Literature DB >> 21570477

The impact of epigenomics on future drug design and new therapies.

Christopher A Hamm1, Fabricio F Costa.   

Abstract

The future of drug design and the development of new therapeutics will rely on our ability to unravel the complexities of the epigenome in normal and disease states. Proper epigenetic regulation is essential for normal differentiation in embryogenesis and development. Conversely, abnormal epigenetic regulation is a feature of complex diseases, including cancer, diabetes, heart disease and other pathologies. Epigenetic therapies hold promise for a wide range of biological applications, from cancer treatment to the establishment of induced pluripotent stem cells. The creation of more specific and effective epigenetic therapies, however, requires a more complete understanding of epigenomic landscapes. Here, we give a historical overview of the epigenomics field and how epigenetic modifications can affect embryo development and disease etiology. We also discuss the impact of current and future epigenetic drugs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570477     DOI: 10.1016/j.drudis.2011.04.007

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  18 in total

1.  Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease.

Authors:  Caroline L Relton; George Davey Smith
Journal:  Int J Epidemiol       Date:  2012-02       Impact factor: 7.196

Review 2.  Epigenetic inheritance of disease and disease risk.

Authors:  Johannes Bohacek; Isabelle M Mansuy
Journal:  Neuropsychopharmacology       Date:  2012-07-11       Impact factor: 7.853

Review 3.  Uncovering epigenetic landscape: a new path for biomarkers identification and drug development.

Authors:  Daiane Teixeira de Oliveira; Renata Guerra-Sá
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

4.  Histone deacetylases expression in atypical teratoid rhabdoid tumors.

Authors:  Simone Treiger Sredni; Abby L Halpern; Christopher A Hamm; Maria de Fátima Bonaldo; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2012-11-10       Impact factor: 1.475

Review 5.  PROTACs for BRDs proteins in cancer therapy: a review.

Authors:  Chao Wang; Yujing Zhang; Shanbo Yang; Wujun Chen; Dongming Xing
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 6.  Epigenetics advancing personalized nanomedicine in cancer therapy.

Authors:  Shujun Liu
Journal:  Adv Drug Deliv Rev       Date:  2012-08-19       Impact factor: 15.470

Review 7.  Epigenetics and miRNA emerge as key regulators of smooth muscle cell phenotype and function.

Authors:  Rachel L Clifford; Cherie A Singer; Alison E John
Journal:  Pulm Pharmacol Ther       Date:  2012-07-16       Impact factor: 3.410

8.  HEMD: an integrated tool of human epigenetic enzymes and chemical modulators for therapeutics.

Authors:  Zhimin Huang; Haiming Jiang; Xinyi Liu; Yingyi Chen; Jiemin Wong; Qi Wang; Wenkang Huang; Ting Shi; Jian Zhang
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

Review 9.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

10.  Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer.

Authors:  Edneia A S Ramos; Mariana Grochoski; Karin Braun-Prado; Gerusa G Seniski; Iglenir J Cavalli; Enilze M S F Ribeiro; Anamaria A Camargo; Fabrício F Costa; Giseli Klassen
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.